TVTX · Travere Therapeutics, Inc.

Summary

Travere Therapeutics, Inc. filed an 8-K on February 19, 2026, disclosing results of operations under Item 2.02 with Exhibit 99.1 press release attached. The filing includes references to analyst consensus EPS context for the period.

Key takeaways

• Item 2.02 Results of Operations disclosed
• Exhibit 99.1 Press release dated 2026-02-19
• 2026-02-19 EPS $0.03 vs est $0.03 (+0.0%)
• Filing date 2026-02-19